7JK Stock Overview
Engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
EQL Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 6.84 |
| 52 Week High | SEK 7.38 |
| 52 Week Low | SEK 2.76 |
| Beta | 0.63 |
| 1 Month Change | 15.15% |
| 3 Month Change | 45.53% |
| 1 Year Change | 145.16% |
| 3 Year Change | 88.95% |
| 5 Year Change | n/a |
| Change since IPO | 95.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7JK | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -0.9% | -0.3% | -0.2% |
| 1Y | 145.2% | 16.5% | 7.0% |
Return vs Industry: 7JK exceeded the German Healthcare industry which returned 16.5% over the past year.
Return vs Market: 7JK exceeded the German Market which returned 7% over the past year.
Price Volatility
| 7JK volatility | |
|---|---|
| 7JK Average Weekly Movement | 6.4% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7JK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 7JK's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 20 | Axel Schorling | www.eqlpharma.com |
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
EQL Pharma AB (publ) Fundamentals Summary
| 7JK fundamental statistics | |
|---|---|
| Market cap | €201.41m |
| Earnings (TTM) | €2.71m |
| Revenue (TTM) | €27.48m |
74.4x
P/E Ratio7.3x
P/S RatioIs 7JK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7JK income statement (TTM) | |
|---|---|
| Revenue | SEK 316.38m |
| Cost of Revenue | SEK 179.73m |
| Gross Profit | SEK 136.66m |
| Other Expenses | SEK 105.48m |
| Earnings | SEK 31.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 1.07 |
| Gross Margin | 43.19% |
| Net Profit Margin | 9.85% |
| Debt/Equity Ratio | 74.9% |
How did 7JK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 11:07 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EQL Pharma AB (publ) is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Commissioned Research |